cyrilzakka/clinical-trials huggingface dataset:
Testing a Shortened Version of the AlAn's Game

It has been demonstrated that behavior on the AlAn's (altruism-antisocial) game is related to Moral Elevation response. Moral Elevation is a positive response to another's act of generosity "of charity, gratitude, fidelity, generosity or any other strong display of virtue". The constellation of emotional, physical and psychological aspects of a Moral Elevation response have been well described. Moral Elevation can be elicited with stimulus stories or videos and measured with self-report questionnaires. The experience of Moral Elevation is associated with subsequent prosocial and affiliative behaviors. Additionally, the research has linked Moral Elevation response with behavior on the AlAn's game. This study will test whether behavior on the AlAn's Short Game v.2 is related to Moral Elevation response and extend prior work by testing whether viewing the Moral Elevation stimulus prior to playing the AlAn's Short Game v.2 is associated with differences in game behavior. The study will also test whether psychopathic traits will correlate with game behavior.

Hypotheses and Specific Aims:

Aim 1: Examine the similarities and differences in behaviors on the AlAn's Short Game v.2 seen with the two Active Trial (AT) types (where Red Cross donation will be reduced and subject will gain money (AT1) vs. where the Red Cross donation will increase and study participants will lose money (AT2).

Hypothesis 1: Number of accepted trials of AT1 and AT2 from session 1 will significantly correlate.

Aim 2: Test the effects of Elevation vs. Nature video on change in AlAn's Short Game v.2 behavior between sessions 1 and 2.

Hypothesis 2: Subjects who view the Elevation stimulus video (study Arm 1) will show increases in prosocial behavior while those watching the Nature video will not.

Aim 3: Test the association between psychopathic traits and Costly Helping and determine whether the influence of Elevation on Costly Helping dissipates with increasing levels of psychopathic traits.

Hypothesis 3: Psychopathic traits, as measured by the Levenson Self Report Psychopathy Scale, will significantly and negatively correlate with the amount of prosocial behavior in session 1.

Hypothesis 4: Using subjects from study Arm 1, change in AlAn's Short game v.2 behavior (session 2 minus session 1) will be negatively correlated with psychopathic trait scores.

Eligibility Criteria:
Inclusion Criteria:

• age 18-25 years

Exclusion Criteria:

• refusal to provide informed consent
Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts

This study is a double-blinded, controlled clinical intervention trial to evaluate the efficacy of duct tape occlusions therapy for the treatment of common warts. 80 patients completed this study, and were randomized 1:1 to receive pads which contained either moleskin+transparent duct tape or moleskin alone. The patients wore the pad over the target wart for 7 days at a time, removed the pad on the evening of the 7th day, and replaced the pad on the 8th day. This cycle was repeated for 8 weeks or until the wart resolved. The hypothesis was that duct tape occlusion therapy would be more therapeutic than moleskin for the treatment of the common wart. However, in our study there was only 21% resolution rate in the duct tape arm vs. 22% in the control group.

ABSTRACT (233 word count)

Objective: To evaluate the efficacy of duct tape occlusion therapy for the treatment of common warts.

Design: A double-blinded, controlled, clinical intervention trial. Setting: Veterans Affairs Medical Center. Participants: A total of 90 immunocompetent adult volunteers with at least one wart measuring between 2-15 mm were enrolled in this study between October 2004 and July 2005; 80 patients completed the study.

Intervention: Patients were randomized using a computer-generated code to receive either pads consisting of moleskin with transparent duct tape (active) or moleskin alone (control). Patients were instructed to wear the pads for 7 consecutive days and leave the pad off on the 7th evening. This process was repeated for 2 months or until the wart resolved, whichever occurred first. Follow-up visits occurred at 1 and 2 months.

Main Outcome Measure: 100% resolution of the wart. Secondary outcomes included change in size of the target wart and recurrence rates at 6 months for warts with complete resolution.

Results: There were no statistically significant differences in the proportions of patients with resolution of the target wart (duct tape=8/39, 21% vs. control=9/41, 22%). Of patients with complete resolution, 75% (6/8) in the duct tape group and 33% (3/9) of those in the control group had recurrence of the target wart by the sixth month.

Conclusions: Occlusive therapy with transparent duct tape is not significantly better than moleskin alone for treatment of common warts in adults.

Eligibility Criteria:
Inclusion Criteria:1) ability to comprehend and provide informed consent; 2) age greater than 18 years old; and 3) at least one common wart, measuring 2-15 millimeters in diameter.

Exclusion Criteria: 1) pregnant or lactating females; 2) treatment of the target wart within the past four weeks by any modality; 3) immunodeficiency state (cancer chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.); 4) genital wart only; 5) a history of hypersensitivity or allergy to adhesive tape; 6) documented allergy to latex; and/or 7) participation in another interventional study or use of any investigational drug within 30 days prior to enrollment.

-
Osteoarticular Infections on Material in Children

The management of osteoarticular infections on equipment is complex. In order to optimize the management of these infections, the French National Authority for Health (HAS) has published good practice recommendations for prosthesis infections in adults. However, in the pediatric population, this type of infection is rarer and their management less well codified.

The aim of this retrospective and descriptive monocentric study is to identify all osteoarticular infections in children under 16 years of age managed at the Montpellier University Hospital from 2014 to 2021, to study the epidemiology and bacterial ecology of these infections and to evaluate the effectiveness of the therapeutic strategy and side effects, long-term sequels


Eligibility Criteria:
Inclusion criteria:

* osteoarticular infections on material in children under 16 years old
* hospitalized at the CHU of Montpellier

Exclusion criteria:

* over 16 years of age
* other types of osteoarticular infections
Comparison of Long vs. Short Acting Anesthesia for Improving Pain Management After Breast Biopsy

This study will evaluate the potential role of a long acting anesthetic (ropivacaine) in providing an extended period of pain relief for patients undergoing ultrasound guided core biopsy of the breast.

The purpose of this study is to evaluate the potential role of a long acting anesthetic (ropivacaine) in providing an extended period of pain relief for patients undergoing ultrasound guided core biopsy of the breast. One group of patients will receive lidocaine alone for local anesthesia. A second group of patients will similarly receive lidocaine prior to tissue sampling, followed by infiltration of the biopsy area with ropivacaine.

Our hypothesis is that patients who receive a long acting anesthetic (ropivacaine) along with the popular short acting anesthetic (lidocaine), will be pain free after the breast biopsy procedure for a longer period of time than the patients who only receive lidocaine (the short acting anesthetic). This will lessen the emotional and physical trauma associated with the procedure and give patients a better experience thereby improving patient care.

Eligibility Criteria:
Inclusion Criteria:

* Patients with breast lesions recommended for biopsy by physician

Exclusion Criteria:

* Patients with breast lesions not recommended for biopsy
* Patients with allergic reactions to lidocaine, ropivacaine, or related anesthetics
PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

This is a prospective, multi-center, randomized, controlled clinical study Of PuraPly® AM and standard of care (SOC) compared to SOC alone for the management of Stage II-IV pressure ulcers located in the gluteal, ischial, hip, sacral, coccygeal, and trochanteric, malleolus, or heel area.

This study seeks to demonstrate how PuraPly® AM performs against standard of care in Stage II-IV Pressure Ulcers through a prospective randomized controlled study design.

Subjects may be enrolled for up to 24 weeks; if healing occurs prior to week 24, a follow up healing confirmation visit shall occur two weeks later to confirm maintenance of complete wound closure and participation may continue up to 24 weeks. Subjects that are randomized to the SOC group have the opportunity to cross over and receive PuraPly AM at week 12 if their index ulcer has not healed; they will then be followed for an additional 12 weeks for up to 24 weeks.

Eligibility Criteria:
Inclusion Criteria:

1. Subject must be at least 18 years of age.
2. Subject has a Stage II-IV pressure ulcer located in the gluteal, ischial, hip, sacral, coccygeal, and trochanteric, malleolus, or heel area.
3. Pressure ulcer should be present for 4 weeks duration and have a ulcer surface area \> 2cm2
4. If multiple ulcers are present, one ulcer must be identified as the index ulcer.
5. The index ulcer is free from active infection at the time of randomization.
6. Willingness to off-load or pressure redistribute ulcer for duration of enrollment
7. The index ulcer has been offloaded for at least 7 days prior to randomization.
8. The index ulcer must have been present for at least 30 days at time of study enrollment.
9. The index ulcer is separated at least 4 cm from all other ulcers at Study Day -7 and Study Day 0 (post-debridement) and has a margin of intact skin sufficient for anchoring of the required study dressing.
10. Subject has read and signed the IRB/IEC approved Informed Consent Form (ICF) before screening procedures are undertaken.

Exclusion Criteria:

1. Presence of signs and symptoms of infection at the index ulcer site, including but not limited to cellulitis, acute osteomyelitis, excessive exudate, gangrene or deep tissue infection
2. The index ulcer is not free of necrotic tissue and is unable to tolerate debridement
3. Non-enteric or unexplored sinus tract
4. Concomitant conditions that in the judgment of the investigator would make the subject inappropriate for entry to the study
5. Subject has a known sensitivity to porcine materials
6. Subject has a known sensitivity to polyhexamethylenebiguanide (PHMB)
Pedagogues Promoting Positive Parenting in a Home-visiting Program in At-risk Families: A RCT of VIPP-SD

Supportive parenting is a strong predictor of positive outcomes for children, and harsh parenting is a risk factor for child development, especially for the child developing externalizing problems (overactive, oppositional, and aggressive behavior). Externalizing problems in preschoolers are predictive of a variety of problems in later childhood. Thus, parents are key targets for change in preventive programs with children at risk for developing externalizing problems. More than 95% of 2-6 year old Danish children spend an average of 7.5 hours, 5 days a week in a daycare setting, thus pedagogues are key frontline staff in the promotion of parental abilities and early childhood mental health. However, a recent Danish study shows that pedagogues experience a need for systematic skills and methods for intervening in families with a child at risk. Attachment-based programs enhancing parental sensitivity and parental sensitive discipline show promising results. This efficacy study examines the Video-feedback Intervention to Promote Positive Parenting and Sensitive Discipline (VIPP-SD)delivered by 22 VIPP-SD trained pedagogues at home-visits to 120 families with a child (1-6 years) identified to be at risk. Pedagogues are supervised by four VIPP municipality psychologists, thus promoting the cross-disciplinary collaboration. The results will point to future identification of families that may (and may not) profit from a pedagogue delivered VIPP-SD intervention, as well as to revise the intervention in order to maximizing its effect, i.e. point to changes to tailor intervention to the particular needs of different families in a Danish context.


Eligibility Criteria:
Inclusion Criteria:

* Child 2-6 year old
* Parent must be more than 18 years old
* Parent must speak and understand Danish
* Family must live in the municipalities of Frederiksberg or Roskilde - and having no intentions of moving out of the municipality before after the intervention has ended
* Parent can attend other treatment initiatives
* Child must attend a daycare center in one of the two municipalities
* Child must be at risk of developing externalizing behavior, i.e. showing signs of overactive, oppositional, and aggressive behavior.

Exclusion criteria

* Sexual or physical abuse by parent
* Parental drug or alcohol abuse
* Child diagnosis of autism
* Child is not considered at risk of developing externalizing behavior problems, but may have other problems, such as delayed language or motordevelopment etc
The Effect of BMI on Hand Grip Force in Healthy Adults

This study will be conducted to investigate the effect of BMI on hand grip force in healthy subjects. The participants in this study will be 90 healthy subjects with right dominant lower limb (49 females and 49 males) they will be recruited from College of Applied Medical Sciences, Jazan University.

Subjects will be categorized according to BMI into three groups:

Group I (normal subjects): 30 individuals (15 male, and 15 female students) with (BMI\<25 kg/m2) Group II (overweight subjects): 30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg/m2).

Group III (obese subjects): 30 individuals (15 male, and 15 female students) (BMI\>30 kg/m2).

Baseline hydraulic hand dynamometer: (Fabrication Enterprises Incorporated, White Plains,New York, USA) will be used to measure the hand grip strength and pinch strength

Eligibility Criteria:
Inclusion Criteria:

1. Subjects would not have any diseases of the central nervous system.
2. Subjects would not have any orthopedic disorders either of the trunk or the lower limbs in the previous year.
3. None of the subjects has history of balance training ( Erkmen et al., 2010, Li Li, 2012) .

Exclusion Criteria:

1. Sign of foot pain, reduced tactile and thermal foot sensibility.
2. Peripheral neuropathy.
3. A history of previous back or abdominal surgery/injury
4. A history of patellofemoral pain syndrome, plantar fasciitis, and back pain .
5. Limb-length discrepancy, and anterior or posterior tibialis dysfunction.
6. Evidence of a systemic or musculoskeletal disease within the past six months (AlAbdulwahab \& Kachanathu, 2016).
HCV RAS Testing in Public Health Programs

Successful treatment of hepatitis C has been reported to be associated with 62-84% reduction in all-cause mortality (deaths), 68-79% reduction in risk of HCC and 90% reduction in risk of liver transplantation. The efficacy of NS5A inhibitors for the treatment of patients chronically infected with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associated substitutions (RASs). Pre-existence of resistance associated substitutions (RASs) to direct antiviral agents (DAAs) reduces sustained virologic response (SVR) rates by 3-53% in hepatitis C virus (HCV) genotype 3 infected patients depending on different predictors and the DAA regimen used. This study will prospectively analyze data from the MukhMantri Punjab Hepatitis C Relief Fund (MMPHCRF) to determine the posttreatment prevalence of various NS5A RASs, and their effect on outcomes of treatment with daclatasvir-sofosbuvir or sofosbuvir-ledipasvirin patients with chronic HCV.

The study aims to assess the prevalence and effect of RASs on sustained virological response (SVR) rates in patients with treatment failure to a regimen containing sofosbuvir and ledipasvir/daclatasvir.


Eligibility Criteria:
Inclusion Criteria:

* All viremic chronic hepatitis C

Exclusion Criteria:

* People with disseminated malignancy, advanced cardiovascular, 18 pulmonary, or neurological disease with short life expectancy were not enrolled
Development of MRI Protocols and Associated Explorations (EEG, NIRS) in Voluntary Patients

Studies that will be carried out on healthy volunteers will have as main objective the development and optimization of the parameters of sequences or the design of the paradigms of stimulation in order to optimize the quality and the relevance of the images realized taking in Taking account of anatomical, functional or metabolic parameters, or integrating new approaches resulting from technical evolutions

The pathologies that interest us in these refinements concern mainly the chronic (or sequellar) brain disorders which can be degenerative, developmental or vascular. The patients who will be recruited will be known patients of our Service (University Clinic of Neuroradiology and MRI) that we follow during checks. The type of examination that will be applied to them, between MRI, EEG and NIRS, will be specified in the consent form. These examinations will not be invoiced either to the patient or to the social security, and the related costs will be borne by our Federative Research Structure or sometimes, when these explorations are upstream of a defined research protocol and funded, They will be financed under this protocol.

Eligibility Criteria:
Inclusion Criteria:

* major voluntary patients
* socially insured.
* Karnofsky score above 60%.
* given their consent.
* absence of contraindication to the MRI examination

Exclusion Criteria:

* Subjects under the age of 18
* pregnant women
* persons referred to in articles L1121-5 to L1121-8 of the CSP.
* Patients with acute illness
Long-term Result of DTPA (Diethylenetriamine Pentaacetate) Chelation for Gadolinium Deposition Disease

This study is aimed at describing the degree of benefit, if any, and the adverse effects, if any, from receiving 5 or more treatment sessions of Gadolinium Deposition Disease using two-day chelation treatment with the chelating agents Calcium Diethylenetriamine pentaacetate (Ca-DTPA) and Zinc Diethylenetriamine pentaacetate (Zn-DTPA).

Potential participants will be invited to contact Dr. Koran by email to receive a telephone screening Informed Consent. Those who provide informed consent will have their questions about the study answered and their interest and eligibility assessed via telephone interview. Those who wish to participate will be sent an Informed Consent for study participation. Those who return the consent will be sent four study questionnaires for completion and return. The returned forms will be reviewed by Dr. Koran or his co-investigator, and a follow-up phone call will be offered via Secure Stanford email. The phone call will involve answering any new questions the participant has, and clarifying the participant's responses to the data collection forms if clarification is needed. Participants who wish to receive a summary of the study's results once it is completed and accepted for publication, will be emailed a summary via Secure Stanford email.

Eligibility Criteria:
Inclusion Criteria:

1. Age 18 or older,
2. Diagnosis of Gadolinium Deposition Disease (GDD) established by treating MD according to current criteria and confirmed by investigator review of screening questionnaire (dx criteria: presence of at least 3 of 8 symptoms-cognitive disturbance, extremity pain, arthralgia, chest wall pain, skin pain, headache, skin induration, and skin hyperpigmentation; and, had an unprovoked 24-hour Gd urine excretion level exceeding the laboratory norm at least 28 days after the symptom-inducing MRI;
3. has had five or more 2-day chelation treatments with Ca-DTPA/Zn-DTPA;
4. will be at least 2 weeks post the last chelation treatment at the time of completing the patient data-gathering questionnaires.
5. no more than 2 years have elapsed since the last DTPA chelation.

Exclusion Criteria:

1. Not fluent in written and spoken English; 2. having impaired hearing that significantly decreases the person's ability to communicate via telephone; 3. Prisoners; 4. Unable to provide informed consent; 5. Participating or having participated in protocols involving a pharmacological treatment of GDD other than DTPA chelation. Note: brief pre- or post-DTPA chelation to prevent GDD symptom flare is not an exclusion criterion.

-
Dermacyd Femina (Lactic Acid) Pocket BR - Photo Evaluation

To demonstrate the absence of photoirritation and photosensitization potential of the product Dermacyd Femina (Lactic Acid) Pocket BR.


Eligibility Criteria:
Inclusion criteria:

* Age between 18 and 60 years old;
* Phototype Skin I,II, III e IV
* Integral skin test in the region;
* Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion;

Exclusion criteria:

* Lactation or gestation
* Use of Antiinflammatory and/or immunosuppression drugs one month before the study;
* Personnel history of atopy;
* History of sensitivity or irritation for topic products;
* Active cutaneous disease;
* Use of new drugs or cosmetics during the study;

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Interaction of Statins and Nondepolarizing Muscle Relaxants

provide evidence for prevention or reduction muscle pain.

The purpose of this study is to determine interaction of statins and nondepolarizing muscle relaxant,In order to provide evidence for prevention or reduction muscle pain.

Eligibility Criteria:
Inclusion Criteria:

* Patients with American Society of Anesthesiologists physical status I-III
* Patients taking statins for at least 3 months and those who had never used statins were considered to be eligible

Exclusion Criteria:

* Orthopedic
* Spinal surgery
* Surgery involving extensive muscle manipulation
* History of liver and kidney failure
* Neuromuscular disease
* Susceptibility to or family history of malignant hyperthermia
* Extensive denervation of skeletal muscle
* Chronic pain syndromes
* Taking medications that might interact with the effect of rocuronium or serum myoglobin difficult intubation
Sex Hormone Binding Globulin, Testosterone and Glycemic Control in Patients With Type 2 Diabetes

Sex hormone-binding globulin(SHBG) is a surrogate marker of insulin resistance. This study aims at the characteristic and clinical significance of SHBG and testosterone in patients with type 2 diabetes(T2D).

The investigators recorded clinical factors, biochemical criterion such as serum levels of glucose and lipids, HbA1c, SHBG, testosterone, insulin, EPO, C-peptide, glucagon, microalbuminuria, glycemic variation via CGM, carotid plaque, ECG and ultrasonic cardiogram in patients with T2D who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to Aprol 2018. The relationship between levels of SHBG, testosterone and glycemic variation/diabetic complications are analysed.

Eligibility Criteria:
Inclusion Criteria:

● Patients with T2D and the diagnostic criteria of T2D is according to the World Health Organization in 1999.

Exclusion Criteria:

* Patients use systemic steroidal anti-inflammatory drugs.
* Patients with an acute infection.
* Patients with acute complication of diabetes.